SCHEMBL4254130

SCHEMBL4254130

O=C(O)c1cc(-c2cccc(F)c2)nc2ccncc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
GAA P10253 1/20 0.61
DHODH Q02127 9/20 0.57
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
CSNK2A2 P19784 1/20 0.54
CSNK2B P67870 1/20 0.54
KDM4E B2RXH2 3/20 0.52
LMNA P02545 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PDE10A Q9Y233 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52
AKR1C1 Q04828 1/20 0.52
HTT P42858 1/20 0.51
KMO O15229 1/20 0.50
AURKA O14965 1/20 0.47
MAPT P10636 1/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251041 0.86 KDM4E (0.69) ALDH1A1GAADHODHKDM4ELMNA
SCHEMBL4252230 0.85 ALDH1A1 (0.69) ALDH1A1GAADHODHMEN1KMT2A
SCHEMBL4248498 0.85 ALDH1A1 (0.54) ALDH1A1DHODHMEN1KMT2ACSNK2A2
SCHEMBL4248571 0.85 KDM4E (0.60) ALDH1A1GAADHODHMEN1KMT2A
SCHEMBL4246561 0.84 DHODH (0.55) ALDH1A1GAADHODHMEN1KMT2A
SCHEMBL31490582 0.84 DHODH (0.80) ALDH1A1GAADHODHMEN1KMT2A
SCHEMBL4248564 0.81 MEN1 (0.61) ALDH1A1DHODHMEN1KMT2ACSNK2A2
SCHEMBL14034221 0.80 CSNK2A2 (0.46) ALDH1A1GAADHODHMEN1KMT2A
SCHEMBL4247440 0.80 ACHE (0.49) ALDH1A1GAAMEN1KMT2ACSNK2A2
SCHEMBL15919374 0.80 ALDH1A1 (0.52) ALDH1A1GAADHODHMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1709045-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2006-10-11 EP disclosed
US-20050171141-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2005-08-04 US disclosed
WO-2005056552-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-06-23 WO disclosed
WO-2005056552-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171141-A1 Modulators of muscarinic receptors CHRM3, CHRM2, CHRM4 ALDH1A1 2677/4885GAA 3344/4885DHODH 3465/4885
US-20090042928-A1 Modulators of muscarinic receptors CHRM3, CHRM2, CHRM4 ALDH1A1 2677/4885GAA 3344/4885DHODH 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.